Clinical Trial Update: A Study to Evaluate Different Dose Levels of GlaxoSmithKline (GSK) Biologicals' Investigational Respiratory Syncytial Virus (RSV) Vaccine (GSK3888550A), Based on the Vaccine Safety and the Antibodies (Body Defences) Produced Following Vaccine Administration, When Given to Healthy Non-pregnant Women [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating different dose levels of an investigational RSV vaccine (GSK3888550A) in healthy non-pregnant women; study completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• GSK3888550A (GSK3888550A)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Respiratory Syncytial Virus Infections | Phase 1 | Status: COMPLETED | Results posted: 2020-04-15